Bone Biologics Corporation has reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a net loss of $666,737 for the quarter, a decrease from a loss of $941,002 in the same period last year. For the nine-month period, the company recorded a net loss of $2.4 million, down from $2.6 million in the prior year. The company continues to operate without generating revenue, as it focuses on the development of its lead product, NELL-1/DBM, a bone regeneration technology.
Operating expenses for the third quarter decreased by 24.8% to $715,274, compared to $951,021 in the same quarter of 2024. This reduction was primarily driven by a significant decrease in research and development costs, which fell by 56.3% to $187,808, attributed to the timing of clinical trials. General and administrative expenses saw a slight increase of 1.2%, totaling $527,466. For the nine-month period, total operating expenses decreased by 6.1% to $2.5 million, with research and development costs also down by 21.7% to $802,994.
In terms of strategic developments, Bone Biologics completed a public offering in June 2025, raising approximately $4.35 million through the issuance of common stock and pre-funded warrants. This capital is expected to support ongoing development activities, particularly as the company prepares for pivotal clinical studies. As of September 30, 2025, the company had cash reserves of $6 million, an increase from $3.3 million at the end of 2024, which is projected to fund operations into the fourth quarter of 2026.
The company has also seen a significant increase in its common stock outstanding, rising to 1,795,260 shares as of September 30, 2025, compared to 492,417 shares at the end of 2024. This increase is a result of the public offering and the exercise of pre-funded warrants. The company continues to face challenges related to its accumulated losses, which have reached approximately $87.4 million since inception, raising concerns about its ability to continue as a going concern without additional financing.
Looking ahead, Bone Biologics remains focused on advancing its clinical trials and obtaining regulatory approvals for its products. The company is actively seeking additional financing to support its operations and product development, although it acknowledges the uncertainty surrounding the availability of such funding. The management's outlook emphasizes the importance of successful clinical trials and regulatory approvals in determining the company's future viability and growth potential.
About Bone Biologics Corp
Bone Biologics Corporation develops recombinant human protein-based medical devices for bone regeneration, focusing on spinal fusion using its proprietary NELL-1 protein combined with demineralized bone matrix (DBM). Targeting orthopedic and spinal surgery markets, the company’s platform aims to improve bone growth outcomes with a safer, targeted approach. Its business model centers on clinical development, regulatory approval, and commercialization of osteopromotive biologics for surgeons and patients with bone defects.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.